PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.85), $0.06 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $213 million versus the consensus estimate of $213.45 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.